CD20×CD3 Bispecific Antibodies in Relapsed/Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety
DOI:
https://doi.org/10.51984/szn7cg42Keywords:
Bispecific antibody, T-cell engager, CD20×CD3, Lymphoma, Diffuse large B-cell lymphoma, Cytokine release syndromeAbstract
CD20×CD3 bispecific antibodies (bsAbs) epcoritamab, glofitamab, mosunetuzumab, and odronextamab have become important treatment options in selected relapsed/refractory (R/R) B-cell lymphoma settings. This narrative review synthesizes trial evidence through August 2026, emphasizing randomized phase 3 data. In R/R diffuse large B-cell lymphoma (DLBCL), glofitamab plus chemotherapy improved overall survival versus chemoimmunotherapy in the randomized STARGLO trial (3-year median OS 25.5 vs 12.5 months; hazard ratio [HR] 0.60); epcoritamab improved progression-free survival but not overall survival versus chemoimmunotherapy in the EPCORE DLBCL-1 topline results. In R/R follicular lymphoma (FL), adding epcoritamab to lenalidomide-rituximab (R2) improved progression-free survival (HR 0.21) and response rates versus R2 alone in the randomized EPCORE FL-1 trial. Single-arm phase 1/2 data show substantial but less certain activity for these agents and for odronextamab in DLBCL and FL. Cytokine release syndrome is the dominant early toxicity, generally low-grade with step-up dosing; immune effector cell-associated neurotoxicity syndrome (ICANS) is less frequent but has been associated with fatal events in the epcoritamab DLBCL registrational population. Infection risk, including fatal infection, is clinically important with prolonged exposure. This is a narrative, non-systematic review; single-arm and uncontrolled results should not be read as directly comparable across agents.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
In a brief statement, the rights relate to the publication and distribution of research published in the journal of the Sebha University, where authors who have published their articles in the Sebha University journal can use or distribute their articles. They reserve all their rights to the published works, such as (but not limited to) the following rights:
- Copyright and other property rights related to the article, such as patent rights.
- Research published in the journal of the University of Sebha and used in its future works, including lectures and books, the right to reproduce articles for their own purposes, and the right to self-archive their articles.
- The right to enter a separate article, or for a non-exclusive distribution of their article with an acknowledgment of its initial publication in the journal of Sebha University.
- Privacy Statement The names and e-mail addresses entered on the Sebha University Journal site will be used for the aforementioned purposes only and for which they were used.
